Cargando…

Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer

BACKGROUND: Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogeneity has not been extensively explored in this type of cancer. Here, their poten...

Descripción completa

Detalles Bibliográficos
Autores principales: Fortis, Sotirios P., Sofopoulos, Michael, Sotiriadou, Nectaria N., Haritos, Christoforos, Vaxevanis, Christoforos K., Anastasopoulou, Eleftheria A., Janssen, Nicole, Arnogiannaki, Niki, Ardavanis, Alexandros, Pawelec, Graham, Perez, Sonia A., Baxevanis, Constantin N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395775/
https://www.ncbi.nlm.nih.gov/pubmed/28428887
http://dx.doi.org/10.1186/s40425-017-0240-7
_version_ 1783229932620480512
author Fortis, Sotirios P.
Sofopoulos, Michael
Sotiriadou, Nectaria N.
Haritos, Christoforos
Vaxevanis, Christoforos K.
Anastasopoulou, Eleftheria A.
Janssen, Nicole
Arnogiannaki, Niki
Ardavanis, Alexandros
Pawelec, Graham
Perez, Sonia A.
Baxevanis, Constantin N.
author_facet Fortis, Sotirios P.
Sofopoulos, Michael
Sotiriadou, Nectaria N.
Haritos, Christoforos
Vaxevanis, Christoforos K.
Anastasopoulou, Eleftheria A.
Janssen, Nicole
Arnogiannaki, Niki
Ardavanis, Alexandros
Pawelec, Graham
Perez, Sonia A.
Baxevanis, Constantin N.
author_sort Fortis, Sotirios P.
collection PubMed
description BACKGROUND: Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogeneity has not been extensively explored in this type of cancer. Here, their potential as prognostic biomarkers was evaluated, depending on their combined densities in the tumor center (TC) and the tumor invasive margin (IM). METHODS: CD8+ and CD163+ cells were quantified by immunohistochemistry of formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from a cohort totaling 162 patients with histologically-confirmed primary invasive non-metastatic ductal breast cancer diagnosed between 2000 and 2015. Clinical follow-up (median 6.9 years) was available for 97 of these patients. RESULTS: Differential densities of CD8+ and CD163+ cells in the combined TC and IM compartments (i.e., high(H)/low(L), respectively for CD8+ cells and the reverse L/H combination for CD163+ cells) were found to have significant prognostic value for survival, and allowed better patient stratification than TNM stage, tumor size, lymph node invasion and histological grade. The combined evaluation of CD8+ and CD163+ cell densities jointly in TC and IM further improves prediction of clinical outcomes based on disease-free and overall survival. Patients having the favorable immune signatures had favorable clinical outcomes despite poor clinicopathological parameters. CONCLUSIONS: Given the important roles of CD8+ and CD163+ cells in regulating opposing immune circuits, adding an assessment of their differential densities to the prognostic biomarker armamentarium in breast cancer would be valuable. Larger validation studies are necessary to confirm these findings. TRIAL REGISTRATIONS: Study code: IRB-ID 6079/448/10-6-13 Date of approval: 10/06/2013 Retrospective study (2000–2010) First patient prospectively enrolled 14/2/2014 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40425-017-0240-7) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-5395775
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53957752017-04-20 Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer Fortis, Sotirios P. Sofopoulos, Michael Sotiriadou, Nectaria N. Haritos, Christoforos Vaxevanis, Christoforos K. Anastasopoulou, Eleftheria A. Janssen, Nicole Arnogiannaki, Niki Ardavanis, Alexandros Pawelec, Graham Perez, Sonia A. Baxevanis, Constantin N. J Immunother Cancer Research Article BACKGROUND: Tumor immune cell infiltrates are essential in hindering cancer progression and may complement the TNM classification. CD8+ and CD163+ cells have prognostic impact in breast cancer but their spatial heterogeneity has not been extensively explored in this type of cancer. Here, their potential as prognostic biomarkers was evaluated, depending on their combined densities in the tumor center (TC) and the tumor invasive margin (IM). METHODS: CD8+ and CD163+ cells were quantified by immunohistochemistry of formalin-fixed, paraffin-embedded (FFPE) tumor tissue samples from a cohort totaling 162 patients with histologically-confirmed primary invasive non-metastatic ductal breast cancer diagnosed between 2000 and 2015. Clinical follow-up (median 6.9 years) was available for 97 of these patients. RESULTS: Differential densities of CD8+ and CD163+ cells in the combined TC and IM compartments (i.e., high(H)/low(L), respectively for CD8+ cells and the reverse L/H combination for CD163+ cells) were found to have significant prognostic value for survival, and allowed better patient stratification than TNM stage, tumor size, lymph node invasion and histological grade. The combined evaluation of CD8+ and CD163+ cell densities jointly in TC and IM further improves prediction of clinical outcomes based on disease-free and overall survival. Patients having the favorable immune signatures had favorable clinical outcomes despite poor clinicopathological parameters. CONCLUSIONS: Given the important roles of CD8+ and CD163+ cells in regulating opposing immune circuits, adding an assessment of their differential densities to the prognostic biomarker armamentarium in breast cancer would be valuable. Larger validation studies are necessary to confirm these findings. TRIAL REGISTRATIONS: Study code: IRB-ID 6079/448/10-6-13 Date of approval: 10/06/2013 Retrospective study (2000–2010) First patient prospectively enrolled 14/2/2014 ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s40425-017-0240-7) contains supplementary material, which is available to authorized users. BioMed Central 2017-04-18 /pmc/articles/PMC5395775/ /pubmed/28428887 http://dx.doi.org/10.1186/s40425-017-0240-7 Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Fortis, Sotirios P.
Sofopoulos, Michael
Sotiriadou, Nectaria N.
Haritos, Christoforos
Vaxevanis, Christoforos K.
Anastasopoulou, Eleftheria A.
Janssen, Nicole
Arnogiannaki, Niki
Ardavanis, Alexandros
Pawelec, Graham
Perez, Sonia A.
Baxevanis, Constantin N.
Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
title Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
title_full Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
title_fullStr Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
title_full_unstemmed Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
title_short Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer
title_sort differential intratumoral distributions of cd8 and cd163 immune cells as prognostic biomarkers in breast cancer
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5395775/
https://www.ncbi.nlm.nih.gov/pubmed/28428887
http://dx.doi.org/10.1186/s40425-017-0240-7
work_keys_str_mv AT fortissotiriosp differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT sofopoulosmichael differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT sotiriadounectarian differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT haritoschristoforos differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT vaxevanischristoforosk differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT anastasopouloueleftheriaa differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT janssennicole differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT arnogiannakiniki differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT ardavanisalexandros differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT pawelecgraham differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT perezsoniaa differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer
AT baxevanisconstantinn differentialintratumoraldistributionsofcd8andcd163immunecellsasprognosticbiomarkersinbreastcancer